Use of Rituximab in the Management of Sjögren’s Syndrome

摘要: Primary Sjogren’s syndrome (pSS) is an autoimmune disease, showing a broad heterogeneity concerning the symptoms, involved organs, as well prognosis. The clinical presentation, in majority of patients, limited to mucosal surfaces, although some patients may show systemic involvement and/or immunological bio-markers strongly associated with higher risk develop lymphoma. assessment disease activity, by using validated scores, at time pSS diagnosis, has been shown be helpful identifying requiring closer follow-up and more-intensive therapeutic management. At present, evidence-based therapy for symptomatic drugs dryness, choice immunosuppressive or biologic agent treatment mainly based on their efficacy other diseases, expert opinion uncontrolled studies. In recent years, given central role B-lymphocytes pathogenesis, B-cell depleting anti-CD20 monoclonal antibody rituximab (RTX) promising, results trials. Although data present literature do not allow draw definitive conclusion RTX, depletion considered option subgroup patients. particular, RTX seems effective early active glandular swelling manifestations.